Can persistent tumor necrosis factor release lead to refractory sarcoidosis?

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 19, Issue 3, 2002, Pages 164-166

  Baughman, Robert P ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR;

CONFERENCE PAPER; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; FIBROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMA; LUNG TRANSPLANTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOIDOSIS; TREATMENT FAILURE; TUBERCULOSIS;

DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; MACROPHAGES, ALVEOLAR; SARCOIDOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036790617     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Baughman RP, Ohmichi M, Lower EE: Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 133-7.
2. Hunninghake GW, Costabel U, Ando M, et al: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
3. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE: Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42.
4. Pueringer RJ, Schwartz DA, Dayton CS, Gilbert SR, Hunninghake GW: The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993; 103: 832-8.
5. Bost TW, Riches DW, Schumacher B, et al: Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-I beta. Am J Respir Cell Mol Biol 1994; 10: 506-13.
6. Baughman RP, Lower EE, Pierson G, Strohofer S: Spontaneous hydrogen peroxide release from alveolar macrophages of patients with active sarcoidosis: comparison with cigarette smokers. J Lab Clin Med 1988; 111: 399-404.
7. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J: Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-92.
8. Baughman RP, Lower EE: The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142: 1268-71.
9. Muller-Quernheim J, Kienast K, Held M. Pfeifer S, Costabel U: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-22.
10. Strieter RM. Remick DG, Ward PA, et al: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6.
11. Spatafora M, Chiappara G, Merendino AM, D'Amico D, Bellia V, Bonsignore G: Theophylline suppresses the release oftumour necrosis factor-alpha by blood monocytes and alveolar macrophages. Eur Respir J 1994; 7: 223-8.
12. Marques LJ, Zheng L. Poulakis N, Guzman J. Costabel U: Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159: 508-11.
13. Zabel P, Entzian P, Dalhoff K, Schlaak M: Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-9.
14. Tramontana JM, Utaipat U, Molloy A, et al: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-97.
15. Moller DR, Wysocka M, Greenlee BM, et al: Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-61.
16. Carlesimo M. Giustini S, Rossi A, Bonaccorsi P, Calvieri S: Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9.
17. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE: Thalidomide for chronic sarcoidosis. Chest 2002; in press
18. Geyer AS, Anhalt GJ, Nousari HC: Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol 2000; 136: 459-60.
19. Lofberg R: Treatment of fistulas in Crohn's disease with infliximab. Gut 1999; 45: 642-3.
20. Lovell DJ, Giannini EH, Reiff A, et al: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-9.
21. Maini R, St Clair EW, Breedveld F, et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-39.
22. Sandborn WJ. Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5: 119-33.
23. Rutgeerts P, D'Haens G, Targan S. et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
24. Kean J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 2001; 345: 1098-104.
25. Baughman RP, Lower EE: Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4.
26. Yee AMF, Pochapin MB: Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis-alpha therapy. Ann Intern Med 2001; 135: 27-31.
27. Ziegenhagen MW, Rothe E, Zissel G, Muller-Quernheim J: Exaggerated TNFa release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-90.
28. Baughman RP, Lower EE: Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 1997; 14: 121-30.
29. Nunley DR, Hattler B, Keenan RJ. et al: Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 93-100.
30. Takizawa H, Satoh M, Okazaki H, et al: Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol 1997; 107: 175-81.
31. Lync, JP, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM: Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev Respir Dis 1992; 145: 1433-9.
32. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN: Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. Am J Respir Crit Care Med 1996; 154: 76-81.
33. Oakley RH, Sar M, Cidlowski JA: The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271: 9550-9.
34. Webster JC, Oakley RH, Jewell CM, Cidlowski JA: Proinfammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocosticoid resistance. Proc Natl Acad Sci U S A 2001; 98: 6865-70.